ARS Pharmaceuticals, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -0.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.55 | $-0.63 | -14.6% | Miss | |
| Q1 FY26 | $-0.53 | $-0.61 | -15.1% | Miss | |
| Q4 FY25 | $-0.42 | $-0.42 | +0.0% | Beat | |
| Q3 FY25 | $-0.45 | $-0.52 | -15.6% | Miss | |
| Q2 FY25 | $-0.41 | $-0.46 | -12.2% | Miss | Q2 FY25 call |
| Q1 FY25 | $-0.35 | $-0.35 | +0.0% | Beat | |
| Q4 FY24 | not reported | $0.52 | not reported | not reported | |
| Q3 FY24 | $-0.18 | $-0.20 | -11.1% | Miss | |
| Q2 FY24 | $-0.12 | $-0.13 | -8.3% | Miss | |
| Q1 FY24 | $-0.11 | $-0.11 | +0.0% | Beat | |
| Q4 FY23 | $-0.14 | $-0.07 | +50.0% | Beat | |
| Q3 FY23 | $-0.18 | $-0.16 | +11.1% | Beat |
Back to SPRY overview · SPRY holders · SPRY KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.